|
US5081227A
(en)
|
1988-03-04 |
1992-01-14 |
La Jolla Cancer Research Foundation |
Germ cell alkaline phosphatase
|
|
FI922220A7
(fi)
*
|
1989-11-17 |
1992-05-15 |
Unilever Nv |
Spesifiset sitoutumisaineet
|
|
US6773669B1
(en)
|
1995-03-10 |
2004-08-10 |
Maxcyte, Inc. |
Flow electroporation chamber and method
|
|
US6090617A
(en)
|
1996-12-05 |
2000-07-18 |
Entremed, Inc. |
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
|
|
US20020004490A1
(en)
|
1999-04-12 |
2002-01-10 |
Dean Nicholas M. |
Antisense modulation of Fas mediated signaling
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
GB9827152D0
(en)
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
EP2314700A1
(en)
|
1999-01-28 |
2011-04-27 |
Medical College of Georgia Research Institute, Inc |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
DK1180123T3
(da)
|
1999-05-27 |
2008-10-13 |
Us Gov Health & Human Serv |
Immunkonjugater, der har höj bindingsaffinitet
|
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
|
US8202846B2
(en)
|
2000-03-16 |
2012-06-19 |
Cold Spring Harbor Laboratory |
Methods and compositions for RNA interference
|
|
WO2001083751A2
(en)
|
2000-04-28 |
2001-11-08 |
Sangamo Biosciences, Inc. |
Methods for binding an exogenous molecule to cellular chromatin
|
|
US7029916B2
(en)
|
2001-02-21 |
2006-04-18 |
Maxcyte, Inc. |
Apparatus and method for flow electroporation of biological samples
|
|
IL158514A0
(en)
|
2001-04-23 |
2004-05-12 |
Amaxa Gmbh |
Buffer solution for electroporation and a method comprising the use of the same
|
|
KR100385905B1
(ko)
|
2001-05-17 |
2003-06-02 |
주식회사 웰진 |
유니진 유래의 안티센스 분자로 구성된 안티센스 라이브러리를 이용한 대규모 유전자 검색 및 기능 분석 방법
|
|
US6485974B1
(en)
|
2001-05-18 |
2002-11-26 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTPN2 expression
|
|
EP2574662B1
(en)
|
2001-08-22 |
2021-08-04 |
Maxcyte, Inc. |
Method for electroporation of biological samples
|
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
AU2002343792A1
(en)
|
2001-11-28 |
2003-06-10 |
Center For Advanced Science And Technology Incubation, Ltd. |
siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
|
|
US20030232410A1
(en)
|
2002-03-21 |
2003-12-18 |
Monika Liljedahl |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
US7399586B2
(en)
|
2002-05-23 |
2008-07-15 |
Ceptyr, Inc. |
Modulation of biological signal transduction by RNA interference
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
AU2003282722A1
(en)
|
2002-10-02 |
2004-04-23 |
Alnylam Pharmaceuticals Inc. |
Therapeutic compositions
|
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
|
WO2004108883A2
(en)
|
2003-06-10 |
2004-12-16 |
Toolgen, Inc. |
Transducible dna-binding proteins
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
DE502004009820D1
(de)
|
2004-03-15 |
2009-09-10 |
Lonza Cologne Ag |
Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
|
|
DK1766057T3
(en)
|
2004-05-12 |
2015-03-02 |
Maxcyte Inc |
Methods and devices related to a regulated flowelektroporationskammer
|
|
KR100853102B1
(ko)
|
2004-06-12 |
2008-08-21 |
주식회사 디지탈바이오테크놀러지 |
중공구조를 갖는 전기천공 장치
|
|
EP1774036A4
(en)
|
2004-06-14 |
2008-10-15 |
Univ Texas At Austin |
GEN-TARGETING IN EUKARYOTIC CELLS BY GROUP II INTRON-RIBONUCLEOPROTEIN PARTICLES
|
|
ES2465467T3
(es)
|
2004-06-14 |
2014-06-05 |
Lonza Cologne Ag |
Procedimiento y disposición de circuito para el tratamiento de material biológico
|
|
KR20070091163A
(ko)
|
2004-11-30 |
2007-09-07 |
맥스시티 인코포레이티드 |
컴퓨터화된 일렉트로포레이션
|
|
WO2006066158A2
(en)
|
2004-12-14 |
2006-06-22 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of mll-af4 and uses thereof
|
|
WO2006124641A2
(en)
|
2005-05-12 |
2006-11-23 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Anti-mesothelin antibodies useful for immunological assays
|
|
CN101355965A
(zh)
|
2005-06-08 |
2009-01-28 |
达纳－法伯癌症研究院 |
通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
|
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
|
ES2398918T3
(es)
|
2005-08-26 |
2013-03-22 |
Dupont Nutrition Biosciences Aps |
Un método y una ordenación para soportar verticalmente elementos de resistencia eléctrica pendientes
|
|
US20070161031A1
(en)
|
2005-12-16 |
2007-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Functional arrays for high throughput characterization of gene expression regulatory elements
|
|
SI2049663T1
(sl)
|
2006-08-11 |
2015-12-31 |
Dow Agrosciences Llc |
Homologna rekombinacija, posredovana z nukleazo s cinkovim prstom
|
|
US8252526B2
(en)
|
2006-11-09 |
2012-08-28 |
Gradalis, Inc. |
ShRNA molecules and methods of use thereof
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
WO2008109532A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fas gene expression and uses thereof
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
US8450112B2
(en)
|
2008-04-09 |
2013-05-28 |
Maxcyte, Inc. |
Engineering and delivery of therapeutic compositions of freshly isolated cells
|
|
DK2310500T3
(en)
|
2008-07-18 |
2015-05-11 |
Maxcyte Inc |
Process for optimizing electroporation
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
JP2012525146A
(ja)
|
2009-04-28 |
2012-10-22 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
細胞透過のための過剰に荷電されたタンパク質
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
HUE041436T2
(hu)
|
2009-12-10 |
2019-05-28 |
Univ Minnesota |
Tal-effektor-közvetített DNS-módosítás
|
|
AU2011219716A1
(en)
|
2010-02-26 |
2012-09-27 |
Cellectis |
Use of endonucleases for inserting transgenes into safe harbor loci
|
|
US8771985B2
(en)
|
2010-04-26 |
2014-07-08 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using zinc-finger nucleases
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
CA3205751A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
WO2013126712A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
AU2013289979A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Methods of assessing the suitability of transduced T cells for administration
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
CA2881981A1
(en)
|
2012-08-20 |
2014-02-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US9409992B2
(en)
|
2012-08-21 |
2016-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP4357457B1
(en)
|
2012-10-23 |
2024-10-16 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
WO2014082163A1
(en)
|
2012-11-28 |
2014-06-05 |
Zhou Youwen |
Tox inhibition for the treatment of cancer
|
|
WO2014089212A1
(en)
|
2012-12-05 |
2014-06-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of metabolic disorders
|
|
EP3363902B1
(en)
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CA2895155C
(en)
|
2012-12-17 |
2021-07-06 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201507026WA
(en)
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
WO2014124267A1
(en)
|
2013-02-07 |
2014-08-14 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
|
|
EP4303232A3
(en)
|
2013-02-15 |
2024-04-17 |
The Regents of The University of California |
Chimeric antigen receptor and methods of use thereof
|
|
EP3628322A1
(en)
|
2013-03-01 |
2020-04-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
|
|
EP2968601A1
(en)
|
2013-03-10 |
2016-01-20 |
Baylor College Of Medicine |
Chemotherapy-resistant immune cells
|
|
WO2014153114A1
(en)
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2014227653B2
(en)
|
2013-03-15 |
2017-04-20 |
The General Hospital Corporation |
Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
|
|
JP6346266B2
(ja)
|
2013-03-21 |
2018-06-20 |
サンガモ セラピューティクス， インコーポレイテッド |
操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊
|
|
EP2981614A1
(en)
|
2013-04-02 |
2016-02-10 |
Bayer CropScience NV |
Targeted genome engineering in eukaryotes
|
|
AU2014248119B2
(en)
|
2013-04-03 |
2019-06-20 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2897579T3
(es)
|
2013-06-10 |
2022-03-01 |
Dana Farber Cancer Inst Inc |
Métodos y composiciones para reducir la inmunosupresión por células tumorales
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US10822606B2
(en)
|
2013-09-27 |
2020-11-03 |
The Regents Of The University Of California |
Optimized small guide RNAs and methods of use
|
|
CN105899665B
(zh)
|
2013-10-17 |
2019-10-22 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
WO2015073867A1
(en)
|
2013-11-15 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Engineering neural stem cells using homologous recombination
|
|
US10787684B2
(en)
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
MX2016007325A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
AU2014361781B2
(en)
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
|
CA2933134A1
(en)
|
2013-12-13 |
2015-06-18 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
WO2015092024A2
(en)
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
ES2939542T3
(es)
|
2014-01-31 |
2023-04-24 |
Factor Bioscience Inc |
Métodos y productos para la producción y la administración de ácido nucleico
|
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
|
US10196608B2
(en)
|
2014-02-21 |
2019-02-05 |
Cellectis |
Method for in situ inhibition of regulatory T cells
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
CA2945320A1
(en)
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
CA2945335A1
(en)
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
WO2015188228A1
(en)
|
2014-06-10 |
2015-12-17 |
Monash University |
Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016057951A2
(en)
|
2014-10-09 |
2016-04-14 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
|
WO2016069282A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
|
US11219634B2
(en)
|
2015-01-21 |
2022-01-11 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US10377988B2
(en)
|
2015-01-23 |
2019-08-13 |
Musc Foundation For Research Development |
Cytokine receptor genes and the use thereof to enhance therapy
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016135559A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
WO2016138034A1
(en)
|
2015-02-24 |
2016-09-01 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
CN107614012A
(zh)
|
2015-04-24 |
2018-01-19 |
加利福尼亚大学董事会 |
使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法
|
|
CA2986755A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
IL295224B2
(en)
|
2015-05-28 |
2025-07-01 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
|
JP6949728B2
(ja)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法
|
|
CA2989858A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
US11643668B2
(en)
|
2015-06-17 |
2023-05-09 |
The Uab Research Foundation |
CRISPR/Cas9 complex for genomic editing
|
|
EP4043556B1
(en)
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
EP3322297B1
(en)
|
2015-07-13 |
2024-12-04 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
EP3202792B1
(en)
|
2015-08-07 |
2024-08-14 |
Shenzhen In Vivo Biomedicine Technology Limited Company |
Chimeric antigen receptor containing intracellular domain of toll-like receptor
|
|
US10072088B2
(en)
|
2015-08-17 |
2018-09-11 |
Janssen Pharmaceutica, Nv |
Anti-BCMA antibodies and uses thereof
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017035659A1
(en)
|
2015-09-01 |
2017-03-09 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variations (cnvs) for genetic disorders and related uses
|
|
US20180258149A1
(en)
*
|
2015-09-17 |
2018-09-13 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
CN117070468A
(zh)
|
2015-10-05 |
2023-11-17 |
精密生物科学公司 |
包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
|
|
US20180327706A1
(en)
|
2015-10-19 |
2018-11-15 |
The Methodist Hospital |
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
|
|
US20180312873A1
(en)
|
2015-10-20 |
2018-11-01 |
10X Genomics, Inc. |
Method and systems for high throughput single cell genetic manipulation
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
JP2019500899A
(ja)
|
2015-11-23 |
2019-01-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作
|
|
EP3383920B1
(en)
|
2015-11-30 |
2024-01-10 |
The Regents of the University of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
|
AU2016369490C1
(en)
|
2015-12-18 |
2021-12-23 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the T cell receptor
|
|
WO2017115128A2
(en)
|
2015-12-30 |
2017-07-06 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
MX2018010924A
(es)
|
2016-03-11 |
2019-02-13 |
Bluebird Bio Inc |
Células efectoras inmunitarias con edición genómica.
|
|
US20170267755A1
(en)
|
2016-03-16 |
2017-09-21 |
Sri International |
Isolated anti-mesothelin antibodies, conjugates and uses thereof
|
|
CN109415687A
(zh)
|
2016-04-07 |
2019-03-01 |
蓝鸟生物公司 |
嵌合抗原受体t细胞组合物
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
AU2017250295B2
(en)
|
2016-04-14 |
2022-08-25 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
US11377637B2
(en)
|
2016-04-15 |
2022-07-05 |
Memorial Sloan Kettering Cancer Center |
Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
|
|
US11499168B2
(en)
|
2016-04-25 |
2022-11-15 |
Universitat Basel |
Allele editing and applications thereof
|
|
WO2017189336A1
(en)
|
2016-04-25 |
2017-11-02 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
|
JP7184648B2
(ja)
|
2016-04-29 |
2022-12-06 |
ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー |
標的核酸の改変のための改善された方法
|
|
CN116850305A
(zh)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
基因工程化细胞及其制备方法
|
|
WO2017210334A1
(en)
|
2016-05-31 |
2017-12-07 |
Massachusetts Institute Of Technology |
Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
|
|
ES2982085T3
(es)
|
2016-06-20 |
2024-10-14 |
Octapharma Ag |
Medios y métodos para modificar alelos múltiples
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
US20190185849A1
(en)
|
2016-06-29 |
2019-06-20 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
JP7195154B2
(ja)
|
2016-07-06 |
2022-12-23 |
セレクティス |
初代免疫細胞における逐次遺伝子編集
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018039084A1
(en)
|
2016-08-20 |
2018-03-01 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeablization of cells
|
|
JP7500195B2
(ja)
|
2016-08-23 |
2024-06-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
EP3516058A1
(en)
|
2016-09-23 |
2019-07-31 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
JP7177047B2
(ja)
|
2016-10-12 |
2022-11-22 |
フェルダン・バイオ・インコーポレーテッド |
ポリペプチドカーゴを標的真核細胞の細胞外間隙からサイトゾルおよび／または核に送達するための合理的に設計された合成ペプチドシャトル剤、その使用、それに関連する方法およびキット
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
EP3541937A4
(en)
|
2016-11-18 |
2020-06-24 |
Christopher Bradley |
REPAIR OF MASSIVELY MULTIPLEXED HOMOLOGICAL TEMPLATE FOR FULL GENERATION
|
|
CN110582301A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和蛋白质有效负载递送的方法和组合物
|
|
CA3096798C
(en)
|
2017-01-09 |
2026-02-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
JP7235391B2
(ja)
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
人工的に操作された免疫細胞
|
|
US10858443B2
(en)
|
2017-05-31 |
2020-12-08 |
Trustees Of Boston University |
Synthetic notch protein for modulating gene expression
|
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
EP3697820A4
(en)
|
2017-10-17 |
2022-01-05 |
The General Hospital Corporation |
PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS
|
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
|
WO2019084495A1
(en)
|
2017-10-27 |
2019-05-02 |
The Trustees Of The University Of Pennsylvania |
IDENTIFICATION OF EPIGENETIC AND TRANSCRIPTIONAL TARGETS TO PREVENT AND REVERSE T-LYMPHOCYTE EXHAUST
|
|
EP3714042A4
(en)
|
2017-11-22 |
2021-08-04 |
La Jolla Institute for Allergy and Immunology |
USE AND PRODUCTION OF MODIFIED IMMUNE CELLS
|
|
PT3737765T
(pt)
|
2018-01-12 |
2022-03-11 |
Curocell Inc |
Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
|
|
WO2019160956A1
(en)
*
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
EP3755712A1
(en)
*
|
2018-02-21 |
2020-12-30 |
Cell Design Labs, Inc. |
Chimeric transmembrane receptors and uses thereof
|
|
US20210054405A1
(en)
|
2018-03-02 |
2021-02-25 |
Generation Bio Co. |
Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
|
|
EP3765608A4
(en)
|
2018-03-15 |
2022-01-12 |
KSQ Therapeutics, Inc. |
GENE REGULATORY COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
|
|
WO2019226998A1
(en)
|
2018-05-25 |
2019-11-28 |
The Regents Of The University Of California |
Genetic engineering of endogenous proteins
|
|
WO2019240934A1
(en)
|
2018-06-12 |
2019-12-19 |
Promab Biotechnologies, Inc. |
Plap-car-effector cells
|
|
CN112823011A
(zh)
|
2018-07-09 |
2021-05-18 |
加利福尼亚大学董事会 |
基于t细胞的免疫疗法的基因靶标
|
|
WO2020072126A2
(en)
|
2018-08-07 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
|
|
SG11202101773WA
(en)
|
2018-08-29 |
2021-03-30 |
Nanjing Legend Biotech Co Ltd |
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
CN110904045A
(zh)
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
US11572560B2
(en)
|
2018-10-03 |
2023-02-07 |
Massachusetts Institute Of Technology |
Splicing-dependent transcriptional gene silencing or activation
|
|
WO2020113029A2
(en)
|
2018-11-28 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020123871A1
(en)
|
2018-12-12 |
2020-06-18 |
The Regents Of The University Of California |
Compositions and methods for modifying a target nucleic acid
|
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
US20220133790A1
(en)
|
2019-01-16 |
2022-05-05 |
Beam Therapeutics Inc. |
Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
|
|
MX2021009357A
(es)
|
2019-02-04 |
2021-11-17 |
Ksq Therapeutics Inc |
Dianas de genes de combinacion para mejorar la inmunoterapia.
|
|
CN113840920A
(zh)
|
2019-03-14 |
2021-12-24 |
加利福尼亚大学董事会 |
合并的敲入筛选和在内源基因座控制下共表达的异源多肽
|
|
WO2020219682A2
(en)
|
2019-04-24 |
2020-10-29 |
St. Jude Children's Research Hospital, Inc. |
Gene knock-outs to improve t cell function
|
|
JP7633180B2
(ja)
|
2019-05-02 |
2025-02-19 |
セリアド オンコロジー エス．アー． |
マルチプレックス化干渉ｒｎａを有する細胞
|
|
SG11202110935RA
(en)
*
|
2019-05-13 |
2021-10-28 |
Dna Twopointo Inc |
Modifications of mammalian cells using artificial micro-rna to alter their properties and the compositions of their products
|
|
CN114555788A
(zh)
*
|
2019-09-06 |
2022-05-27 |
阿维塔斯有限公司 |
免疫细胞工程化用于体外细胞治疗
|
|
DE102019214466A1
(de)
|
2019-09-23 |
2021-03-25 |
Henkel Ag & Co. Kgaa |
Mittel zum Färben von keratinischem Material mit Aminosilikon, farbgebender Verbindung und ethoxyliertem Fettsäureester
|
|
CN114761084B
(zh)
|
2019-09-24 |
2023-10-27 |
加利福尼亚大学董事会 |
具有铰链结构域的Notch受体
|
|
CN114729025A
(zh)
|
2019-09-24 |
2022-07-08 |
加利福尼亚大学董事会 |
用于配体依赖性转录调控的新型受体
|
|
WO2021061872A1
(en)
|
2019-09-24 |
2021-04-01 |
The Regents Of The University Of California |
Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
CN120905142A
(zh)
|
2019-11-20 |
2025-11-07 |
卡瑟里克斯私人有限公司 |
用于提供具有增强功能的免疫细胞的方法
|
|
US20220389383A1
(en)
|
2019-11-27 |
2022-12-08 |
Board Of Regents, The University Of Texas System |
Large-scale combined car transduction and crispr gene editing of nk cells
|
|
JP7698321B2
(ja)
|
2019-11-27 |
2025-06-25 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ
|
|
KR20220108793A
(ko)
|
2019-11-27 |
2022-08-03 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Msc 세포의 대규모 조합된 car 형질 도입 및 crispr 유전자 편집
|
|
CN115052897B
(zh)
|
2020-01-28 |
2024-06-21 |
湖南远泰生物技术有限公司 |
PLAP-CD3ε双特异性抗体
|
|
CN115380047A
(zh)
|
2020-01-29 |
2022-11-22 |
印希比股份有限公司 |
Cd28单结构域抗体及其多价和多特异性构建体
|
|
US20230183709A1
(en)
|
2020-04-09 |
2023-06-15 |
The Regents Of The University Of California |
Humanized notch receptors with hinge domain
|
|
IL302315A
(en)
|
2020-10-26 |
2023-06-01 |
Arsenal Biosciences Inc |
Secure port sites
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
WO2022150831A1
(en)
|
2021-01-07 |
2022-07-14 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Car cells and polyspecific binding molecules for treating solid tumor
|
|
US20220235380A1
(en)
*
|
2021-01-26 |
2022-07-28 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US12592129B2
(en)
|
2021-10-05 |
2026-03-31 |
Aristocrat Technologies, Inc. |
Electronic gaming machine with symbols streaming adjacent an active reel matrix with reel expansion and symbol absorption processes
|
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|